Účtovná hodnota akcie spoločnosti Neovacs S.A
Aká je hodnota metriky Účtovná hodnota akcie spoločnosti Neovacs S.A?
Hodnota metriky Účtovná hodnota akcie spoločnosti Neovacs S.A. je 0.00
Aká je definícia metriky Účtovná hodnota akcie?
Účtovná hodnota akcie (Book/Share) sa rovná majetku spoločnosti mínus záväzky spoločnosti podelené počtom vydaných akcií.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Účtovná hodnota akcie spoločností v sektore Health Care sektor na EURONEXT v porovnaní so spoločnosťou Neovacs S.A
Čomu sa venuje spoločnosť Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Firmy s metrikou účtovná hodnota akcie podobnou spoločnosti Neovacs S.A
- Hodnota metriky Účtovná hodnota akcie spoločnosti Cybergun S.A je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti The GO2 People je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti Rhythm Biosciences je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti Orion Metals je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti Clever Leaves je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti Independent Oil & Gas Plc je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti Neovacs S.A je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti Environmental Clean Technologies je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti MJ je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti Intra je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti Key Petroleum je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti CF Finance Acquisition II je 0.00
- Hodnota metriky Účtovná hodnota akcie spoločnosti RMG je 0.00